{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:36Z","timestamp":1794002616987,"version":"4.8.0"},"reference-count":90,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>As a synthetic analogue of vasopressin, desmopressin or DDAVP has well established hemostatic properties. We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, liver cirrhosis, and pregnancy, followed by illustrative examples of its broad efficacy from our local practice. In brief, DDAVP acts to release von Willebrand factor (VWF) and factor VIII from endogenously stored reserves, thereby correcting plasma deficiencies present in mild to moderately affected patients with hemophilia A and VWD. Thus, DDAVP represents a non-transfusional therapy for these disorders. Typically, a trial of DDAVP is arranged to assess individual responsiveness before employing DDAVP clinically, since there is individual variation in responsiveness. Thereafter, DDAVP can be utilized in responsive patients for clinical use and provides a factor replacement sparing strategy in these patients for some clinical situations. Nevertheless, DDAVP is best applied as a factor replacement sparing strategy, especially for minor procedures or short-term use.<\/jats:p>","DOI":"10.3390\/biom15070967","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:19:27Z","timestamp":1751887167000},"page":"967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Review of Desmopressin Use in Bleeding Disorders: An Unsung Hero?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5767-508X","authenticated-orcid":false,"given":"Benjamin","family":"Reardon","sequence":"first","affiliation":[{"name":"Joint Medical Program, School of Medicine and Public Health, University of Newcastle, Callaghan, NSW 2145, Australia"},{"name":"Haematology Department, Calvary Mater Hospital Newcastle, Waratah, NSW 2298, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pasalic","sequence":"additional","affiliation":[{"name":"Haematology Department, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia"},{"name":"Westmead Clinical School, University of Sydney, Westmead, NSW 2145, Australia"},{"name":"Sydney Centres for Thrombosis and Haemostasis, Research and Education Network (REN) and Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-1661","authenticated-orcid":false,"given":"Emmanuel J.","family":"Favaloro","sequence":"additional","affiliation":[{"name":"Haematology Department, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia"},{"name":"Sydney Centres for Thrombosis and Haemostasis, Research and Education Network (REN) and Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia"},{"name":"School of Dentistry and Medical Sciences, Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW 2650, Australia"},{"name":"School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2516.2007.01610.x","article-title":"The use of desmopressin in von Willebrand disease: The experience of the first 30 years (1977\u20132007)","volume":"14","author":"Federici","year":"2008","journal-title":"Haemophilia"},{"key":"ref_2","unstructured":"Michelson, A.D. (2019). Desmopressin (DDAVP). Platelets, Academic Press. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1146\/annurev.me.41.020190.000415","article-title":"Desmopressin: A non transfusional agent","volume":"41","author":"Mannucci","year":"1990","journal-title":"Annu. Rev. Med."},{"key":"ref_4","first-page":"363","article-title":"Proceedings: The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man","volume":"27","author":"Cash","year":"1974","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand\u2019s diseases","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"ref_6","first-page":"3983","article-title":"The life cycle of coagulation factor VIII in view 456 of its structure and function","volume":"92","author":"Lenting","year":"1998","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1172\/JCI114107","article-title":"Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid","volume":"836","author":"Arai","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102143","DOI":"10.1016\/j.rpth.2023.102143","article-title":"Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: Considerations based on geography and resources","volume":"7","author":"Favaloro","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_11","unstructured":"World Federation for Hemophilia Annual Global Survey. Available online: https:\/\/wfh.org\/usa\/research-and-data-collection\/annual-global-survey\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood.2024026804","article-title":"DDAVP response and its determinants in bleeding disorders: A systematic review and meta-analysis","volume":"145","author":"Laan","year":"2025","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/j.1538-7836.2009.03595.x","article-title":"Molecular and phenotypic 462 determinants of the response to desmopressin in adult patients with mild hemophilia A","volume":"7","author":"Castaman","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/ajh.2830360406","article-title":"Plasmin generation and fibrin(ogen)olysis following desmopressin infusion","volume":"36","author":"Takahashi","year":"1991","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jth.13576","article-title":"Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Desborough","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","article-title":"Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP)","volume":"82","author":"Mannucci","year":"1992","journal-title":"Br. J. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1055\/s-0040-1713735","article-title":"Navigating the Myriad of von Willebrand Factor Assays","volume":"40","author":"Favaloro","year":"2020","journal-title":"H\u00e4mostaseologie"},{"key":"ref_20","first-page":"3531","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3324\/haematol.2017.180059","article-title":"Desmopressin in moderate hemophilia A patients: A treatmentworth considering","volume":"103","author":"Loomans","year":"2018","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/hematology.2019000064","article-title":"New advances in the diagnosis of von Willebrand disease","volume":"2019","author":"Sharma","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_23","first-page":"2029","article-title":"Diagnostic approach to von Willebrand disease","volume":"125","author":"Ng","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0037-1619606","article-title":"Acquired von Willebrand syndrome 2004: International Registry--diagnosis and management from online to bedside","volume":"24","author":"Federici","year":"2004","journal-title":"H\u00e4mostaseologie"},{"key":"ref_25","first-page":"2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches","volume":"92","author":"Federici","year":"1998","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V116.21.238.238","article-title":"Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) in Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results from the International Study Group on DDAVP in VWD in a Cohort of 229 Patients","volume":"116","author":"Federici","year":"2010","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/hae.14801","article-title":"Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes","volume":"29","author":"Chandrakumaran","year":"2023","journal-title":"Haemophilia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.V110.11.713.713","article-title":"Incidence and determinants of bleeding in different types of von Willebrand disease: Results of the first prospective multicenter study on 814 Italian patients","volume":"110","author":"Federici","year":"2007","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.1365-2141.2000.02067.x","article-title":"Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders","volume":"109","author":"Nolan","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1182\/bloodadvances.2021006757","article-title":"Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease","volume":"6","author":"Atiq","year":"2022","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2147\/JBM.S266791","article-title":"Why is misdiagnosis of von Willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations","volume":"12","author":"Colonne","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1055\/s-0037-1614018","article-title":"Acquired von Willebrand syndrome: Data from an international registry","volume":"84","author":"Federici","year":"2000","journal-title":"Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/j.seminhematol.2005.11.003","article-title":"Acquired von Willebrand syndrome: An underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders","volume":"43","author":"Federici","year":"2006","journal-title":"Semin. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3324\/haematol.2018.187567","article-title":"Use of desmopressin in the treatment of hemophilia A: Towards a golden jubilee","volume":"103","author":"Mannucci","year":"2018","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3476(83)80526-5","article-title":"DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand disease","volume":"102","author":"Warrier","year":"1983","journal-title":"J. Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2257.1984.tb00548.x","article-title":"Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand\u2019s disease. A study of 43 patients","volume":"6","author":"Mariani","year":"1984","journal-title":"Clin. Lab. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.7326\/0003-4819-103-1-6","article-title":"Response of patients with mild and moderate hemophilia A and von Willebrand\u2019s disease to treatment with desmopressin","volume":"103","author":"Kasper","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1046\/j.1365-2141.2002.03507.x","article-title":"DDAVP challenge tests in boys with mild\/moderate haemophilia A","volume":"117","author":"Blanchette","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100281","DOI":"10.1016\/j.rpth.2023.100281","article-title":"Desmopressin in nonsevere hemophilia A: Patient perspectives on use and efficacy","volume":"7","author":"Romano","year":"2023","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.12439","article-title":"Desmopressin response in hemophilia A patients with FVIII:C < 0.10 IU mL(-1.)","volume":"12","author":"Stoof","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH10-03-0151","article-title":"Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review","volume":"104","author":"Franchini","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an anti-haemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Greist","year":"2015","journal-title":"Haemophilia"},{"key":"ref_46","first-page":"39","article-title":"Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.2008.001743","article-title":"International recommendations on the diagnosis and treatment of patients with acquired hemophilia A","volume":"94","author":"Baudo","year":"2009","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/jth.13007","article-title":"Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding","volume":"13","author":"Swieringa","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand\u2019s disease","volume":"60","author":"Weiss","year":"1977","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3324\/haematol.11460","article-title":"Thrombin-generating capacity in patients with von Willebrand\u2019s disease","volume":"92","author":"Rugeri","year":"2007","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF00320926","article-title":"Gray platelet syndrome: Selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover","volume":"50","author":"Kohler","year":"1985","journal-title":"Blut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V67.4.1148.1148","article-title":"Controlled trial of desmopressinin liver cirrhosis and other conditions associated with a prolonged bleeding time","volume":"67","author":"Mannucci","year":"1986","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.2830330108","article-title":"Use of DDAVP in inherited and acquired platelet dysfunctions","volume":"33","author":"Hathaway","year":"1990","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ajh.2830300307","article-title":"Hermansky-Pudlak syndrome: Correction of bleeding time by 1-desamino-8-D-arginine vasopressin","volume":"30","author":"Wijermans","year":"1989","journal-title":"Am. J. Hematol."},{"key":"ref_57","first-page":"540","article-title":"Platelet aggregation at high shear is impaired inpatients with congenital defects of platelet secretion and is corrected by DDAVP: Correlation with the bleeding time","volume":"125","author":"Cattaneo","year":"1995","journal-title":"J. Lab. Clin. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1055\/s-0038-1646056","article-title":"Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome","volume":"58","author":"Pfueller","year":"1987","journal-title":"Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1600-0609.1991.tb01274.x","article-title":"Bernard-Soulier syndrome in two Swedish families: Effect of DDAVP on bleeding time","volume":"46","author":"Waldenstrom","year":"1991","journal-title":"Eur. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0049-3848(92)90088-R","article-title":"Failure of DDAVP to shorten the prolonged bleeding time of two patients with congenital afibrinogenemia","volume":"68","author":"Castaman","year":"1992","journal-title":"Thromb. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/pbc.20210","article-title":"Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome","volume":"44","author":"Cordova","year":"2005","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1055\/s-0038-1649884","article-title":"Mechanisms of platelet dysfunction and response to DDAVP inpatients with congenital platelet function defects. A double-blind placebo-controlled trial","volume":"74","author":"Rao","year":"1995","journal-title":"Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0049-3848(93)90041-L","article-title":"Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time","volume":"69","author":"Castaman","year":"1993","journal-title":"Thromb. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(84)91393-X","article-title":"Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders","volume":"1","author":"Kobrinsky","year":"1984","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0049-3848(87)90170-8","article-title":"DDAVP induced correction of prolonged bleeding time in patients with congenital platelet function defects","volume":"45","author":"Schulman","year":"1987","journal-title":"Thromb. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0049-3848(99)00102-4","article-title":"Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion","volume":"96","author":"Cattaneo","year":"1999","journal-title":"Thromb. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00043426-199221000-00005","article-title":"Effect of platelet count on the DDAVP-induced shortening of the bleeding time in thrombocytopenic Gaucher\u2019s patients","volume":"14","author":"Parker","year":"1992","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_68","first-page":"584","article-title":"Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies","volume":"82","author":"Castaman","year":"1997","journal-title":"Haematologica"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.ATV.13.3.393","article-title":"Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine","volume":"13","author":"Cattaneo","year":"1993","journal-title":"Arterioscler. Thromb."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Tsui, P.Y., Cheung, C.W., Lee, Y., Leung, S.W., and Ng, K.F. (2015). The effectiveness of low-dose desmopressin in improving hypothermia-induced impairment of primary haemostasis under influence of aspirin\u2014A randomized controlled trial. BMC Anesthesiol., 15.","DOI":"10.1186\/s12871-015-0061-5"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1056\/NEJM198301063080102","article-title":"Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia","volume":"308","author":"Mannucci","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ajh.2830310106","article-title":"Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia","volume":"31","author":"Mannucci","year":"1989","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000166822","article-title":"Intranasal deamino-8-Darginine vasopressin shortens the bleeding time in uremia","volume":"4","author":"Shapiro","year":"1984","journal-title":"Am. J. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/01.CIR.77.6.1319","article-title":"Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?","volume":"77","author":"Rocha","year":"1988","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM198911233212104","article-title":"A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery","volume":"321","author":"Hackmann","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"785","DOI":"10.14423\/SMJ.0000000000000578","article-title":"Transfusion requirements in ESRD patients admitted with GI hemorrhage undergoing inpatient endoscopy","volume":"109","author":"McCartney","year":"2016","journal-title":"South. Med. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(87)91849-6","article-title":"Improvement in the hemostatic defect of uremia after treatment with recombinant human erythropoietin","volume":"2","author":"Moia","year":"1987","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Reardon, B., Pasalic, L., and Favaloro, E.J. (2024). The Role of Viscoelastic Testing in Assessing Hemostasis: A Challenge to Standard Laboratory Assays?. J. Clin. Med., 13.","DOI":"10.3390\/jcm13123612"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.3748\/wjg.v27.i23.3290","article-title":"Viscoelastic tests in liver disease: Where do we stand now?","volume":"27","author":"Buliarca","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0038-1647318","article-title":"Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis","volume":"64","author":"Cattaneo","year":"1990","journal-title":"Thromb. Haemost."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bmj.291.6506.1377","article-title":"Desmopressin and bleeding time in patients with cirrhosis","volume":"291","author":"Burroughs","year":"1985","journal-title":"Br. J. Med."},{"key":"ref_82","first-page":"59","article-title":"Hemostatic and hemodynamic effects of vasopressin analogue DDAVP in patients with cirrhosis","volume":"27","author":"Lopez","year":"1997","journal-title":"Acta Gastroenterol. Latinoam."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/hep.1840180514","article-title":"Randomized controlled trial of desmopressin plus terlipressin and terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double blind study","volume":"18","author":"Arcidiacono","year":"1993","journal-title":"Hepatology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/liv.12765","article-title":"Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis","volume":"35","author":"Arshad","year":"2015","journal-title":"Liver Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00006254-199807000-00025","article-title":"DDAVP use During pregnancy: An analysis of its safety for mother and child","volume":"53","author":"Ray","year":"1998","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jtha.2023.09.021","article-title":"Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder: A systematic literature review","volume":"22","author":"Romano","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.thromres.2008.10.008","article-title":"Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: Differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?","volume":"123","author":"Favaloro","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hae.14204","article-title":"How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types","volume":"27","author":"Favaloro","year":"2021","journal-title":"Haemophilia"},{"key":"ref_89","first-page":"CD009824","article-title":"Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders","volume":"2","author":"Karanth","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1160\/TH10-04-0220","article-title":"Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history","volume":"104","author":"Meschengieser","year":"2010","journal-title":"Thromb. Haemost."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/7\/967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:05:00Z","timestamp":1760033100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/7\/967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":90,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["biom15070967"],"URL":"https:\/\/doi.org\/10.3390\/biom15070967","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]}}}